Terms: = Brain cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Diagnosis
61 results:
1. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play.
Satgunaseelan L; Sy J; Shivalingam B; Sim HW; Alexander KL; Buckland ME
Pathology; 2024 Mar; 56(2):158-169. PubMed ID: 38233331
[TBL] [Abstract] [Full Text] [Related]
3. The evolution of spinal cord surgery: history, people, instruments, and results.
Shimony N; Fehnel K; Abbott IR; Jallo GI
Childs Nerv Syst; 2023 Oct; 39(10):2687-2700. PubMed ID: 37658937
[TBL] [Abstract] [Full Text] [Related]
4. Pediatric Precision Medicine at the National cancer Center Japan: Prospective Genomic Study of Pediatric Patients with cancer as Part of the TOP-GEAR Project.
Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
[TBL] [Abstract] [Full Text] [Related]
5. Utility of Comprehensive Genomic Profiling for Precise diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Makino K; Otani Y; Fujii K; Ishida J; Hirano S; Suruga Y; Washio K; Nishida K; Yanai H; Tomida S; Ennishi D; Date I
Acta Med Okayama; 2023 Jun; 77(3):323-330. PubMed ID: 37357634
[TBL] [Abstract] [Full Text] [Related]
6. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
Massimino M; Vennarini S; Buttarelli FR; Antonelli M; Colombo F; Minasi S; Pecori E; Ferroli P; Giussani C; Schiariti M; Schiavello E; Biassoni V; Erbetta A; Chiapparini L; Nigro O; Boschetti L; Gianno F; Miele E; Modena P; De Cecco L; Pollo B; Barretta F
J Neurooncol; 2023 Jul; 163(3):577-586. PubMed ID: 37326761
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic Utility of GATA3 and ISL1 in Differentiating Neuroblastoma From Other Pediatric Malignant Small Round Blue Cell Tumors.
Mohanty SK; Diwaker P; Mishra SK; Jha S; Lobo A; Panda SP; Sharma S; Kumar M; Arora S; Mallik V; Jain D; Jain E; Chakrabarti I; Varshney J; Beg A; Dixit M; Baisakh MR; Naik S; Sahoo SK; Akgul M; Balzer BL; Amin MB; Parwani AV
Int J Surg Pathol; 2024 Apr; 32(2):294-303. PubMed ID: 37312579
[TBL] [Abstract] [Full Text] [Related]
8. Genomic profiles of IDH-mutant gliomas: mycn-amplified IDH-mutant astrocytoma had the worst prognosis.
Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH
Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778
[TBL] [Abstract] [Full Text] [Related]
9. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.
Gianno F; Giovannoni I; Cafferata B; Diomedi-Camassei F; Minasi S; Barresi S; Buttarelli FR; Alesi V; Cardoni A; Antonelli M; Puggioni C; Colafati GS; Carai A; Vinci M; Mastronuzzi A; Miele E; Alaggio R; Giangaspero F; Rossi S
Pathologica; 2022 Dec; 114(6):422-435. PubMed ID: 36534421
[TBL] [Abstract] [Full Text] [Related]
10. Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.
Wieczorek A; Stefanowicz J; Hennig M; Adamkiewicz-Drozynska E; Stypinska M; Dembowska-Baginska B; Gamrot Z; Woszczyk M; Geisler J; Szczepanski T; Skoczen S; Ussowicz M; Pogorzala M; Janczar S; Balwierz W
BMC Cancer; 2022 Jun; 22(1):701. PubMed ID: 35752779
[TBL] [Abstract] [Full Text] [Related]
11. A Clinicopathological and Molecular Analysis of Sellar/Suprasellar Neurocytoma Mimicking Pituitary Adenoma.
Zhang L; Fu W; Zheng L; Song F; Chen Y; Jiang C; Xing Z; Hu C; Ye Y; Zhang S; Yan X; Wang X
Front Endocrinol (Lausanne); 2022; 13():861540. PubMed ID: 35663322
[TBL] [Abstract] [Full Text] [Related]
12. Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
[TBL] [Abstract] [Full Text] [Related]
13. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
[TBL] [Abstract] [Full Text] [Related]
14. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract] [Full Text] [Related]
15. Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics.
Crosier S; Hicks D; Schwalbe EC; Williamson D; Leigh Nicholson S; Smith A; Lindsey JC; Michalski A; Pizer B; Bailey S; Bown N; Cuthbert G; Wharton SB; Jacques TS; Joshi A; Clifford SC
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):736-747. PubMed ID: 33826763
[TBL] [Abstract] [Full Text] [Related]
16. IDH-mutant gliomas with additional class-defining molecular events.
Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S
Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213
[TBL] [Abstract] [Full Text] [Related]
17. ETMR: a tumor entity in its infancy.
Lambo S; von Hoff K; Korshunov A; Pfister SM; Kool M
Acta Neuropathol; 2020 Sep; 140(3):249-266. PubMed ID: 32601913
[TBL] [Abstract] [Full Text] [Related]
18. BET and Aurora Kinase A inhibitors synergize against mycn-positive human glioblastoma cells.
Čančer M; Drews LF; Bengtsson J; Bolin S; Rosén G; Westermark B; Nelander S; Forsberg-Nilsson K; Uhrbom L; Weishaupt H; Swartling FJ
Cell Death Dis; 2019 Nov; 10(12):881. PubMed ID: 31754113
[TBL] [Abstract] [Full Text] [Related]
19. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract] [Full Text] [Related]
20. mycn amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract] [Full Text] [Related]
[Next]
